Search Results
Your search for Staff matches 6670 pages
Showing 5201 - 5250Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
Half of Surveyed Cancer Researchers Report Their Work Is on Hold Due to the COVID-19 Pandemic
A survey of American Cancer Society grantees found that about half reported their cancer research has been halted as a result of the COVID-19 pandemic. The American Cancer Society reached out to all of its funded researchers to assess the state of their projects and collect information to guide...
FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for the following indications: Adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or...
Ongoing Efforts Toward Vaccine Development for COVID-19
Coronavirus disease 2019 (COVID-19) is spreading throughout the world, and vaccine developers have responded with unprecedented speed. Since the COVID-19 genome sequence was released in January, human trials of an experimental vaccine candidate have already begun in the Seattle area. Although the...
Global COVID-19 Observatory and Resource Center for Childhood Cancer
St. Jude Children’s Research Hospital, in partnership with the International Society of Paediatric Oncology (SIOP), has launched the Global COVID-19 Observatory and Resource Center for Childhood Cancer. The website offers health-care providers around the world a space to share the latest...
Breast Surgeon Kristin L. Brill, MD, Joins Sidney Kimmel Cancer Center
Kristin L. Brill, MD, has joined the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) in Philadelphia as Enterprise Director of Breast Oncology. Dr. Brill brings expertise in a comprehensive range of services for patients with malignant and benign diseases, including breast-conserving surgery,...
Larry Kwak, MD, PhD, Named AIMBE Fellow
City of Hope recently announced that Larry Kwak, MD, PhD, has been inducted into the 2020 Class of American Institute for Medical and Biological Engineering (AIMBE) Fellows. Dr. Kwak is Vice President and Deputy Director of City of Hope’s Comprehensive Cancer Center. He has pioneered breakthrough...
Aria Vaishnavi, PhD, Receives NCI’s Pathway to Independence Award
Aria Vaishnavi, PhD, a postdoctoral fellow at the Huntsman Cancer Institute at the University of Utah, has received the first annual National Cancer Institute (NCI) Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00). The “Early K99” grant supports...
Fox Chase Cancer Center Welcomes Andres F. Correa, MD
Fox Chase Cancer Center announced that Andres F. Correa, MD, has joined the Department of Surgery in the Urologic Oncology Division as Assistant Professor. Dr. Correa, w ho was a Society of Urologic Oncology Fellow at Fox Chase, is returning to the center after serving as Attending Surgeon and...
Parker Institute for Cancer Immunotherapy Appoints Frederic Pla, PhD, as Chief Operating Officer
The Parker Institute for Cancer Immunotherapy (PICI) recently announced the appointment of Frederic Pla, PhD, as its Chief Operating Officer (COO). Dr. Pla will lead day-to-day operations and work with the Institute’s leadership team to establish goals for performance, expansion, and sustainable...
Grace and Forgiveness
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Understanding Patient-Reported Outcomes in Cancer Trials: A Beginner’s Guide
Patient-reported outcomes are measures used in clinical trials to capture aspects of a patient’s health condition, reported directly by the patient, without introduction of bias from third parties. They are distinct from the physical toxicities reported by clinicians1 and are collected using a...
American Cancer Society Awards New Research, Training Grants
The American Cancer Society (ACS) has approved funding for 79 research and training grants, totaling $36,165,100 in the first of two grant cycles for 2020. Grant applications were reviewed and approved remotely in light of the coronavirus epidemic. The grants will fund investigators at 59...
Timothy Chan, MD, PhD, Named Director of Cleveland Clinic’s Center for Immunotherapy and Precision Immuno-Oncology
Timothy Chan, MD, PhD, has been appointed Director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic. Dr. Chan will lead the new center to bring together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related...
Kimlin T. Ashing, PhD, on Tobacco and Vape Shops in Neighborhoods With Lower-Income and Minority Populations
Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number of tobacco and vape shops, increased use of electronic nicotine delivery systems, and lower-priced tobacco products. This...
Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab
Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed preliminary antitumor activity as a monotherapy and in combination with nivolumab in a variety of heavily pretreated patients with...
Grant A. McArthur, MBBS, PhD, on Melanoma: IMspire150 Trial of Atezolizumab, Cobimetinib, and Vemurafenib
Grant A. McArthur, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses phase III results from a study of previously untreated patients with BRAF V600 mutation–positive advanced melanoma. His team evaluated whether combining vemurafenib and cobimetinib with atezolizumab improved the...
Steven J. O’Day, MD, on Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG
Steven J. O’Day, MD, of the John Wayne Cancer Institute, discusses phase II results for the combination of pembrolizumab with a novel innate immune activator, Imprime PGG, as second-line treatment for patients with metastatic triple-negative breast cancer ( Abstract CT073).
Prioritizing Patients With Metastatic Disease for Palliative Radiotherapy
In anticipation of how the COVID-19 pandemic might impact oncology care as the coronavirus spread across New York City, radiation oncologists with expertise in the management of metastatic disease and inpatient oncologic emergencies at Memorial Sloan Kettering Cancer Center (MSK) met in late winter ...
FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of olaparib (Lynparza) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in...
Distinct New MDS Subtype Proposed Based on Presence of Genetic Mutation
In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The...
SGO 2020: Wee1 Inhibition in Recurrent Uterine Serous Carcinoma
In a clinical trial in patients with recurrent uterine serous carcinoma, one-third of study participants responded to treatment with the Wee1 inhibitor adavosertib, according to data presented by Liu et al at a virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s...
Laura C. Michaelis, MD: In My Experience Question 5
For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.
Laura C. Michaelis, MD: In My Experience Question 4
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia? Recorded April 24, 2020.
Laura C. Michaelis, MD: In My Experience Question 2
Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic? Recorded April 24, 2020.
Laura C. Michaelis, MD: In My Experience Question 1
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia? Recorded April 24, 2020.
Mehdi Hamadani, MD: In My Experience Question 6
Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic? Recorded April 21, 2020.
Mehdi Hamadani, MD: In My Experience Question 5
For community oncologists treating patients with non-Hodgkin lymphoma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 21, 2020.
Mehdi Hamadani, MD: In My Experience Question 4
How have the activities of the Center for International Blood and Marrow Transplant Research been affected by the COVID-19 pandemic? Recorded April 21, 2020.
Mehdi Hamadani, MD: In My Experience Question 3
During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma? Recorded April 21, 2020.
Mehdi Hamadani, MD: In My Experience Question 2
During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission? Recorded April 21, 2020.
Mehdi Hamadani, MD: In My Experience Question 1
Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma? Recorded April 21, 2020.
William Dale, MD, PhD, on Best Practices for Special Populations During the COVID-19 Pandemic
William Dale, MD, PhD, of City of Hope National Medical Center, discusses vulnerable populations—older adults and those with psychosocial or mental health concerns—and reviews best practices for treatment decisions, social distancing, and maintaining emotional health. Recorded April 15, 2020.
FDA Approves Capmatinib for Patients With Metastatic NSCLC With Confirmed MET Exon 14 Skipping
On May 6, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by...
Mortality Rate of Patients With Cancer and COVID-19 in a New York Hospital
Patients with cancer who were infected with COVID-19 were much more likely to die from the disease than those without cancer, according to research from physician-researchers at Montefiore Health System and Albert Einstein College of Medicine. Their findings were published by Mehta et al in Cancer...
AACR 2020: Atezolizumab Alone or in Combination With Cobimetinib for Biliary Tract Cancer
A randomized multicenter study of a combination of immunotherapy with a targeted therapy improved cancer control for some patients with biliary tract cancer, according to research presented by Yarchoan et al at the American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract...
Issues With Travel Faced by Patients Undergoing Lu-177 Dotatate Radiation Therapy
A team of researchers and patient advocates have addressed the challenges related to traveling after receiving radiation therapy involving Lu-177 dotatate in a study published by Kendi et al in The Journal of Nuclear Medicine. Due to the residual radiation activity of Lu-177 dotatate, some patients ...
Lajos Pusztai, MD, PhD, on Breast Cancer: I-SPY2 Trial on Durvalumab, Olaparib, and Paclitaxel
Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses study results on durvalumab in combination with olaparib and paclitaxel as neoadjuvant treatment in patients with high-risk HER2-negative stage II/III breast cancer. Compared with patients who received chemotherapy alone, the combination...
Saad Z. Usmani, MD: In My Experience Question 5
For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.
Christopher D'Avella, MD, on Utilizing a Specialized Urgent Care Center for Patients With Cancer
Christopher D'Avella, MD, of Fox Chase Cancer Center, discusses the impact of his institution’s oncologic urgent care center, designed to triage patients and prevent hospital admissions. Patients who presented to the direct referral unit had lower health-care expenses vs those who went to the...
Pam Baker DeGuzman, PhD, on Assessing Distress During Telemedicine Visits With Rural Survivors of Head and Neck Cancer
Pam Baker DeGuzman, PhD, of the University of Virginia School of Nursing, discusses her study findings on the use of the NCCN Distress Thermometer, which identified and addressed distress in patients treated for head and neck cancer who were then referred to speech pathologists, lymphedema...
AI Model Accurately Classifies Colorectal Polyps From Histopathologic Slides
An artificial intelligence (AI) model for automated classification of colorectal polyps could benefit cancer screening programs by improving efficiency, reproducibility, and accuracy, as well as reducing access barriers to pathology services. In a new study published by Wei et al in JAMA Network...
FDA Issues Emergency Use Authorization for Remdesivir for Treatment of Severe COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as low...
ASCO Survey on Early Impact of COVID-19 on the Performance of Oncology Clinical Trials
An article by Waterhouse et al in JCO Oncology Practice presented results of a recent ASCO survey of clinical programs exploring the early impact of the COVID-19 pandemic on the performance of oncology clinical trials. Results highlighted the numerous issues faced by the programs, steps that are...
Saad Z. Usmani, MD: In My Experience Question 4
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 3
Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 2
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma? Recorded April 24, 2020.
Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland
Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, talks about the adjustments to cancer care that he and his colleagues have made, how and when they employ telemedicine, and whether the technology could change the future for clinical practice. Filmed April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 1
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible? Recorded April 24, 2020.
